TREA

Techniques for use with nerve tissue

Follow

Information

  • Patent Grant
  • 10383685
  • Patent Number
    10,383,685
  • Date Filed
    Thursday, May 5, 2016
    8 years ago
  • Date Issued
    Tuesday, August 20, 2019
    5 years ago
Information
Abstract
A method is provided, comprising: (1) applying an excitatory current to renal nerve fibers of a subject; (2) determining a change in a parameter of the subject in response to the excitatory current, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject; (3) in response to the change, deciding whether to ablate the renal nerve fibers; and (4) in response to the deciding, applying ablation energy to the renal nerve fibers. Other embodiments are also described.
Description
BACKGROUND

Hypertension is a prevalent condition in the general population, particularly in older individuals. Sympathetic nervous pathways, such as those involving the renal nerve, are known to play a role in regulating blood pressure. Ablation of renal nerve tissue from the renal artery is a known technique for treating hypertension.


SUMMARY OF THE INVENTION

Techniques are described for using blood pressure parameters, derived from arterial blood pressure waveforms, to facilitate (i) selecting a subject for renal nerve ablation, (ii) defining more specifically a condition (e.g., a pathology) of the subject, (iii) locating target ablation sites within a renal artery of the subject, (iv) deciding on a modality of ablation energy to be used, and/or (v) monitoring the progress and/or success of an ablation procedure.


For some applications the techniques described are performed generally manually, e.g., by a physician. For some applications the techniques described are at least partly automated, e.g., using a device comprising a control unit, a transluminally-advanceable longitudinal member such as a catheter, and one or more electrodes at a distal portion of the longitudinal member.


There is therefore provided, in accordance with an application of the present invention, a method, including:


applying an excitatory current to renal nerve fibers of a subject;


determining a change in a parameter of the subject in response to the excitatory current, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject;


in response to the change, deciding whether to ablate the renal nerve fibers; and


in response to the deciding, applying ablation energy to the renal nerve fibers.


In an application:


applying the excitatory current includes applying the excitatory current to renal nerve fibers proximate to a first location of a renal artery wall,


deciding whether to ablate the renal nerve fibers includes deciding whether to ablate the renal nerve fibers proximate to the first location, and


the method further includes:

    • applying the excitatory current to renal nerve fibers proximate to a second location of a renal artery wall;
    • determining a second change in the parameter in response to the excitatory current applied to the renal nerve fibers proximate to the second location; and
    • in response to the second change, deciding whether to ablate the renal nerve fibers proximate to the second location.


There is further provided, in accordance with an application of the present invention, a method, including:


measuring a first value of a parameter of a subject while the subject is at rest, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject;


applying an excitatory current to renal nerve fibers of a subject;


while applying the excitatory current, measuring a second value of the parameter;


in response to a difference between the first value and the second value, deciding whether to ablate the renal nerve fibers; and


in response to the deciding, applying ablation energy to the renal nerve fibers.


There is further provided, in accordance with an application of the present invention, a method, including:


applying an excitatory current to renal nerve fibers of a subject;


determining a change in a parameter of the subject in response to the excitatory current, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject;


in response to the change, selecting an ablation modality from a plurality of ablation modalities; and


in response to the selecting, ablating the renal nerve fibers using the selected ablation modality.


There is further provided, in accordance with an application of the present invention, a method, including:


applying a first application of excitatory current to renal nerve fibers of a subject;


determining a first change in a parameter of the subject in response to the first application of excitatory current, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject;


subsequently, applying a first application of ablating energy to the renal nerve fibers;


subsequently, applying a second application of excitatory current to renal nerve fibers of a subject;


determining a second change in the parameter in response to the second application of excitatory current;


determining a difference between the first change and the second change;


deciding whether to apply a second application of ablation energy to the renal nerve fibers; and


in response to the deciding, applying the second application of ablation energy to the renal nerve fibers.


There is further provided, in accordance with an application of the present invention, a method, including:


transluminally advancing a distal portion of a longitudinal member of a device into a renal artery of a subject;


operating the device to drive an electrode disposed on the distal portion of the longitudinal member to apply an excitatory current to nerve tissue of the renal artery;


receiving (i) a first value, the first value being indicative of a parameter of the subject before a start of the application of the current, and (ii) a second value, the second value being indicative of the parameter of the subject after a start of the application of the current, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject;


determining if a difference between the first value and the second value is smaller than a threshold difference; and


in response to the determining:

    • only if the determined difference is smaller than the threshold difference, withdrawing the longitudinal member from the subject without having applied ablation energy to the renal artery.


There is further provided, in accordance with an application of the present invention, apparatus including:


a transluminal electrode catheter, including:

    • a flexible shaft, dimensioned for advancement of a distal portion of the shaft into a renal artery of a subject;
    • a plurality of electrodes disposed at the distal portion of the shaft; and
    • an arterial blood pressure sensor; and


a control unit, electrically coupled to the catheter, and configured to:

    • use the sensor to measure a first value of a parameter of the subject while the subject is at rest, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject,
    • drive at least one of the electrodes to apply an excitatory current to renal nerve fibers of the subject,
    • while applying the excitatory current, use the blood pressure sensor to measure a second value of the parameter,
    • determine if a difference between the first value and the second value is greater than a threshold difference, and
    • in response to the determining:
      • only if the determined difference is greater than the threshold difference, enable an ablation function of the control unit.


There is further provided, in accordance with an application of the present invention, a method, including:


applying an excitatory current to renal nerve fibers of a subject;


determining a change in a parameter of the subject in response to the excitatory current, the parameter of the subject being a skewness of an arterial pressure wave of the subject;


in response to the change, deciding whether to ablate the renal nerve fibers; and


in response to the deciding, applying ablation energy to the renal nerve fibers.


In an application:


applying the excitatory current includes applying the excitatory current to renal nerve fibers proximate to a first location of a renal artery wall,


deciding whether to ablate the renal nerve fibers includes deciding whether to ablate the renal nerve fibers proximate to the first location, and


the method further includes:

    • applying the excitatory current to renal nerve fibers proximate to a second location of a renal artery wall;
    • determining a second change in the parameter in response to the excitatory current applied to the renal nerve fibers proximate to the second location; and
    • in response to the second change, deciding whether to ablate the renal nerve fibers proximate to the second location.


There is further provided, in accordance with an application of the present invention, a method, including:


measuring a first value of a parameter of a subject while the subject is at rest, the parameter being skewness of an arterial pressure wave of the subject;


applying an excitatory current to renal nerve fibers of a subject;


while applying the excitatory current, measuring a second value of the parameter;


in response to a difference between the first value and the second value, deciding whether to ablate the renal nerve fibers; and


in response to the deciding, applying ablation energy to the renal nerve fibers.


There is further provided, in accordance with an application of the present invention, a method, including:


applying an excitatory current to renal nerve fibers of a subject;


determining a change in a parameter of the subject in response to the excitatory current, the parameter of the subject being skewness of an arterial pressure wave of the subject;


in response to the change, selecting an ablation modality from a plurality of ablation modalities; and


in response to the selecting, ablating the renal nerve fibers using the selected ablation modality.


There is further provided, in accordance with an application of the present invention, a method, including:


applying a first application of excitatory current to renal nerve fibers of a subject;


determining a first change in a parameter of the subject in response to the first application of excitatory current, the parameter of the subject being skewness of an arterial pressure wave of the subject;


subsequently, applying a first application of ablating energy to the renal nerve fibers;


subsequently, applying a second application of excitatory current to renal nerve fibers of a subject;


determining a second change in the parameter in response to the second application of excitatory current;


determining a difference between the first change and the second change;


deciding whether to apply a second application of ablation energy to the renal nerve fibers; and


in response to the deciding, applying the second application of ablation energy to the renal nerve fibers.


There is further provided, in accordance with an application of the present invention, a method, including:


transluminally advancing a distal portion of a longitudinal member of a device into a renal artery of a subject;


operating the device to drive an electrode disposed on the distal portion of the longitudinal member to apply an excitatory current to nerve tissue of the renal artery;


receiving (i) a first value, the first value being indicative of a parameter of the subject before a start of the application of the current, and (ii) a second value, the second value being indicative of the parameter of the subject after a start of the application of the current, the parameter being skewness of an arterial pressure wave of the subject;


determining if a difference between the first value and the second value is smaller than a threshold difference; and


in response to the determining:

    • only if the determined difference is smaller than the threshold difference, withdrawing the longitudinal member from the subject without having applied ablation energy to the renal artery.


There is further provided, in accordance with an application of the present invention, apparatus including:


a transluminal electrode catheter, including:

    • a flexible shaft, dimensioned for advancement of a distal portion of the shaft into a renal artery of a subject;
    • a plurality of electrodes disposed at the distal portion of the shaft; and
    • an arterial blood pressure sensor; and


a control unit, electrically coupled to the catheter, and configured to:

    • use the sensor to measure a first value of a parameter of the subject while the subject is at rest, the parameter being skewness of an arterial pressure wave of the subject,
    • drive at least one of the electrodes to apply an excitatory current to renal nerve fibers of the subject,
    • while applying the excitatory current, use the blood pressure sensor to measure a second value of the parameter,
    • determine if a difference between the first value and the second value is greater than a threshold difference, and
    • in response to the determining:
      • only if the determined difference is greater than the threshold difference, enable an ablation function of the control unit.


There is further provided, in accordance with an application of the present invention, a method, including:


applying an excitatory current to renal nerve fibers of a subject;


determining a change in a parameter of the subject in response to the excitatory current, the parameter of the subject being a heart rate of the subject;


in response to the change, deciding whether to ablate the renal nerve fibers; and


in response to the deciding, applying ablation energy to the renal nerve fibers.


In an application:


applying the excitatory current includes applying the excitatory current to renal nerve fibers proximate to a first location of a renal artery wall,


deciding whether to ablate the renal nerve fibers includes deciding whether to ablate the renal nerve fibers proximate to the first location, and


the method further includes:

    • applying the excitatory current to renal nerve fibers proximate to a second location of a renal artery wall;
    • determining a second change in the parameter in response to the excitatory current applied to the renal nerve fibers proximate to the second location; and
    • in response to the second change, deciding whether to ablate the renal nerve fibers proximate to the second location.


There is further provided, in accordance with an application of the present invention, a method, including:


measuring a first value of a parameter of a subject while the subject is at rest, the parameter being a heart rate of the subject;


applying an excitatory current to renal nerve fibers of a subject;


while applying the excitatory current, measuring a second value of the parameter;


in response to a difference between the first value and the second value, deciding whether to ablate the renal nerve fibers; and


in response to the deciding, applying ablation energy to the renal nerve fibers.


There is further provided, in accordance with an application of the present invention, a method, including:


applying an excitatory current to renal nerve fibers of a subject;


determining a change in a parameter of the subject in response to the excitatory current, the parameter of the subject being a heart rate of the subject;


in response to the change, selecting an ablation modality from a plurality of ablation modalities; and


in response to the selecting, ablating the renal nerve fibers using the selected ablation modality.


There is further provided, in accordance with an application of the present invention, a method, including:


applying a first application of excitatory current to renal nerve fibers of a subject;


determining a first change in a parameter of the subject in response to the first application of excitatory current, the parameter of the subject being a heart rate of the subject;


subsequently, applying a first application of ablating energy to the renal nerve fibers;


subsequently, applying a second application of excitatory current to renal nerve fibers of a subject;


determining a second change in the parameter in response to the second application of excitatory current;


determining a difference between the first change and the second change;


deciding whether to apply a second application of ablation energy to the renal nerve fibers; and


in response to the deciding, applying the second application of ablation energy to the renal nerve fibers.


There is further provided, in accordance with an application of the present invention, a method, including:


transluminally advancing a distal portion of a longitudinal member of a device into a renal artery of a subject;


operating the device to drive an electrode disposed on the distal portion of the longitudinal member to apply an excitatory current to nerve tissue of the renal artery;


receiving (i) a first value, the first value being indicative of a parameter of the subject before a start of the application of the current, and (ii) a second value, the second value being indicative of the parameter of the subject after a start of the application of the current, the parameter being a heart rate of the subject;


determining if a difference between the first value and the second value is smaller than a threshold difference; and


in response to the determining:

    • only if the determined difference is smaller than the threshold difference, withdrawing the longitudinal member from the subject without having applied ablation energy to the renal artery.


There is further provided, in accordance with an application of the present invention, apparatus including:


a transluminal electrode catheter, including:

    • a flexible shaft, dimensioned for advancement of a distal portion of the shaft into a renal artery of a subject;
    • a plurality of electrodes disposed at the distal portion of the shaft; and
    • an arterial blood pressure sensor; and


a control unit, electrically coupled to the catheter, and configured to:

    • use the sensor to measure a first value of a parameter of the subject while the subject is at rest, the parameter being a heart rate of the subject,
    • drive at least one of the electrodes to apply an excitatory current to renal nerve fibers of the subject,
    • while applying the excitatory current, use the blood pressure sensor to measure a second value of the parameter,
    • determine if a difference between the first value and the second value is greater than a threshold difference, and
    • in response to the determining:
      • only if the determined difference is greater than the threshold difference, enable an ablation function of the control unit.


There is further provided, in accordance with an application of the present invention, a method, including:


applying an excitatory current to renal nerve fibers of a subject;


determining a change in a parameter of the subject in response to the excitatory current, the parameter of the subject being an augmentation index of an arterial pressure wave of the subject;


in response to the change, deciding whether to ablate the renal nerve fibers; and


in response to the deciding, applying ablation energy to the renal nerve fibers.


In an application:


applying the excitatory current includes applying the excitatory current to renal nerve fibers proximate to a first location of a renal artery wall,


deciding whether to ablate the renal nerve fibers includes deciding whether to ablate the renal nerve fibers proximate to the first location, and


the method further includes:

    • applying the excitatory current to renal nerve fibers proximate to a second location of a renal artery wall;
    • determining a second change in the parameter in response to the excitatory current applied to the renal nerve fibers proximate to the second location; and
    • in response to the second change, deciding whether to ablate the renal nerve fibers proximate to the second location.


There is further provided, in accordance with an application of the present invention, a method, including:


measuring a first value of a parameter of a subject while the subject is at rest, the parameter being an augmentation index of an arterial pressure wave of the subject;


applying an excitatory current to renal nerve fibers of a subject;


while applying the excitatory current, measuring a second value of the parameter;


in response to a difference between the first value and the second value, deciding whether to ablate the renal nerve fibers; and


in response to the deciding, applying ablation energy to the renal nerve fibers.


There is further provided, in accordance with an application of the present invention, a method, including:


applying an excitatory current to renal nerve fibers of a subject;


determining a change in a parameter of the subject in response to the excitatory current, the parameter of the subject being an augmentation index of an arterial pressure wave of the subject;


in response to the change, selecting an ablation modality from a plurality of ablation modalities; and


in response to the selecting, ablating the renal nerve fibers using the selected ablation modality.


There is further provided, in accordance with an application of the present invention, a method, including:


applying a first application of excitatory current to renal nerve fibers of a subject;


determining a first change in a parameter of the subject in response to the first application of excitatory current, the parameter of the subject being an augmentation index of an arterial pressure wave of the subject;


subsequently, applying a first application of ablating energy to the renal nerve fibers;


subsequently, applying a second application of excitatory current to renal nerve fibers of a subject;


determining a second change in the parameter in response to the second application of excitatory current;


determining a difference between the first change and the second change;


deciding whether to apply a second application of ablation energy to the renal nerve fibers; and


in response to the deciding, applying the second application of ablation energy to the renal nerve fibers.


There is further provided, in accordance with an application of the present invention, a method, including:


transluminally advancing a distal portion of a longitudinal member of a device into a renal artery of a subject;


operating the device to drive an electrode disposed on the distal portion of the longitudinal member to apply an excitatory current to nerve tissue of the renal artery;


receiving (i) a first value, the first value being indicative of a parameter of the subject before a start of the application of the current, and (ii) a second value, the second value being indicative of the parameter of the subject after a start of the application of the current, the parameter being an augmentation index of an arterial pressure wave of the subject;


determining if a difference between the first value and the second value is smaller than a threshold difference; and


in response to the determining:

    • only if the determined difference is smaller than the threshold difference, withdrawing the longitudinal member from the subject without having applied ablation energy to the renal artery.


There is further provided, in accordance with an application of the present invention, apparatus including:


a transluminal electrode catheter, including:

    • a flexible shaft, dimensioned for advancement of a distal portion of the shaft into a renal artery of a subject;
    • a plurality of electrodes disposed at the distal portion of the shaft; and
    • an arterial blood pressure sensor; and


a control unit, electrically coupled to the catheter, and configured to:

    • use the sensor to measure a first value of a parameter of the subject while the subject is at rest, the parameter being an augmentation index of an arterial pressure wave of the subject,
    • drive at least one of the electrodes to apply an excitatory current to renal nerve fibers of the subject,
    • while applying the excitatory current, use the blood pressure sensor to measure a second value of the parameter,
    • determine if a difference between the first value and the second value is greater than a threshold difference, and
    • in response to the determining:
      • only if the determined difference is greater than the threshold difference, enable an ablation function of the control unit.


There is further provided, in accordance with an application of the present invention, a method, including:


applying an excitatory current to renal nerve fibers of a subject;


determining a change in a parameter of the subject in response to the excitatory current, the parameter of the subject being a diastolic decay time constant of an arterial pressure wave of the subject;


in response to the change, deciding whether to ablate the renal nerve fibers; and


in response to the deciding, applying ablation energy to the renal nerve fibers.


In an application:


applying the excitatory current includes applying the excitatory current to renal nerve fibers proximate to a first location of a renal artery wall,


deciding whether to ablate the renal nerve fibers includes deciding whether to ablate the renal nerve fibers proximate to the first location, and


the method further includes:

    • applying the excitatory current to renal nerve fibers proximate to a second location of a renal artery wall;
    • determining a second change in the parameter in response to the excitatory current applied to the renal nerve fibers proximate to the second location; and
    • in response to the second change, deciding whether to ablate the renal nerve fibers proximate to the second location.


There is further provided, in accordance with an application of the present invention, a method, including:


measuring a first value of a parameter of a subject while the subject is at rest, the parameter being a diastolic decay time constant of an arterial pressure wave of the subject;


applying an excitatory current to renal nerve fibers of a subject;


while applying the excitatory current, measuring a second value of the parameter;


in response to a difference between the first value and the second value, deciding whether to ablate the renal nerve fibers; and


in response to the deciding, applying ablation energy to the renal nerve fibers.


There is further provided, in accordance with an application of the present invention, a method, including:


applying an excitatory current to renal nerve fibers of a subject;


determining a change in a parameter of the subject in response to the excitatory current, the parameter of the subject being a diastolic decay time constant of an arterial pressure wave of the subject;


in response to the change, selecting an ablation modality from a plurality of ablation modalities; and


in response to the selecting, ablating the renal nerve fibers using the selected ablation modality.


There is further provided, in accordance with an application of the present invention, a method, including:


applying a first application of excitatory current to renal nerve fibers of a subject;


determining a first change in a parameter of the subject in response to the first application of excitatory current, the parameter of the subject being a diastolic decay time constant of an arterial pressure wave of the subject;


subsequently, applying a first application of ablating energy to the renal nerve fibers;


subsequently, applying a second application of excitatory current to renal nerve fibers of a subject;


determining a second change in the parameter in response to the second application of excitatory current;


determining a difference between the first change and the second change;


deciding whether to apply a second application of ablation energy to the renal nerve fibers; and


in response to the deciding, applying the second application of ablation energy to the renal nerve fibers.


There is further provided, in accordance with an application of the present invention, a method, including:


transluminally advancing a distal portion of a longitudinal member of a device into a renal artery of a subject;


operating the device to drive an electrode disposed on the distal portion of the longitudinal member to apply an excitatory current to nerve tissue of the renal artery;


receiving (i) a first value, the first value being indicative of a parameter of the subject before a start of the application of the current, and (ii) a second value, the second value being indicative of the parameter of the subject after a start of the application of the current, the parameter being a diastolic decay time constant of an arterial pressure wave of the subject;


determining if a difference between the first value and the second value is smaller than a threshold difference; and


in response to the determining:

    • only if the determined difference is smaller than the threshold difference, withdrawing the longitudinal member from the subject without having applied ablation energy to the renal artery.


There is further provided, in accordance with an application of the present invention, apparatus including:


a transluminal electrode catheter, including:

    • a flexible shaft, dimensioned for advancement of a distal portion of the shaft into a renal artery of a subject;
    • a plurality of electrodes disposed at the distal portion of the shaft; and
    • an arterial blood pressure sensor; and


a control unit, electrically coupled to the catheter, and configured to:

    • use the sensor to measure a first value of a parameter of the subject while the subject is at rest, the parameter being a diastolic decay time constant of an arterial pressure wave of the subject,
    • drive at least one of the electrodes to apply an excitatory current to renal nerve fibers of the subject,
    • while applying the excitatory current, use the blood pressure sensor to measure a second value of the parameter,
    • determine if a difference between the first value and the second value is greater than a threshold difference, and
    • in response to the determining:
      • only if the determined difference is greater than the threshold difference, enable an ablation function of the control unit.


There is further provided, in accordance with an application of the present invention, a method, including:


transluminally advancing an electrode into a renal artery of a subject;


while the subject is at rest, measuring a first value of a first parameter and a first value of a second parameter, the first parameter and the second parameter selected from the group consisting of: (i) a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject, (ii) a skewness of the arterial pressure wave of the subject, (iii) a heart rate of the subject, (iv) an augmentation index of the arterial pressure wave of the subject, and (v) a diastolic decay constant of the arterial pressure wave of the subject;


applying an excitatory current to renal nerve fibers of a subject;


while applying the excitatory current, measuring a second value of the first parameter and a second value of the second parameter;


determining (i) a first difference between the first value of the first parameter and the second value of the first parameter, and (ii) a second difference between the first value of the second parameter and the second value of the second parameter; and


in response to the first difference and the second difference, diagnosing a pathology of the subject.


In an application, the method further includes:


while the subject is at rest, measuring a first value of a third parameter selected from the group;


while applying the excitatory current, measuring a second value of the third parameter; and


determining a third difference between the first value of the third parameter and the second value of the third parameter, and diagnosing the pathology in response includes diagnosing the pathology in response to the first difference, the second difference, and the third difference.


In an application, the method further includes:


while the subject is at rest, measuring a first value of a fourth parameter selected from the group;


while applying the excitatory current, measuring a second value of the fourth parameter; and


determining a fourth difference between the first value of the fourth parameter and the second value of the fourth parameter, and diagnosing the pathology in response includes diagnosing the pathology in response to the first difference, the second difference, the third difference, and the fourth difference.


In an application, the method further includes:


while the subject is at rest, measuring a first value of a fifth parameter selected from the group;


while applying the excitatory current, measuring a second value of the fifth parameter; and


determining a fifth difference between the first value of the fifth parameter and the second value of the fifth parameter, and diagnosing the pathology in response includes diagnosing the pathology in response to the first difference, the second difference, the third difference, the fourth difference, and the fifth difference.


The present invention will be more fully understood from the following detailed description of applications thereof, taken together with the drawings, in which:





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A, 1B, and 1C show a table of evaluated parameters, which spans across FIGS. 1A, 1B, and 1C, in accordance with some applications of the invention;



FIGS. 2, 3, and 4 are schematic illustrations showing arterial pressure waves, with annotations explaining some of the parameters of FIGS. 1A, 1B, and 1C, in accordance with some applications of the invention;



FIGS. 5, 6, 7, 8, and 9 are flow charts showing at least some steps in respective techniques for use with nerve tissue, in accordance with some applications of the invention; and



FIG. 10 is a schematic illustration of a system for ablating and/or stimulating nerve tissue of a blood vessel of a subject, in accordance with some applications of the present invention.





DETAILED DESCRIPTION OF EMBODIMENTS

Reference is made to FIGS. 1A-C, 2, 3, and 4. FIGS. 1A-C show a table of evaluated parameters, which spans across FIGS. 1A-C, in accordance with some applications of the invention. FIGS. 2, 3, and 4 are schematic illustrations showing arterial pressure waves, with annotations explaining some of the parameters of FIGS. 1A-C, in accordance with some applications of the invention.


Experiments were performed in a porcine model. Arterial blood pressure was monitored before, during, and after excitation of (i.e., induction of action potentials in) a renal nerve. Various parameters derived from the resulting trace were evaluated, in order to determine which respond clearly (e.g., a quantitatively large change) and reliably (e.g., qualitatively similarities in changes between animals, such as changing in the same direction in each animal) to renal nerve excitation.


The evaluated parameters were ranked according to the results of the experiments; the top ten parameters appear in the table that spans FIGS. 1A-C.


dP/dT_max is the maximal derivative (dP/dT) of the pressure wave during systolic upstroke (i.e., the fastest rate of increase in arterial pressure during the systolic upstroke). (In the interpretations column, beta_1, alpha_2, and alpha_1 refer to subtypes of adrenergic receptor.) dP/dT_max is illustrated in FIG. 2. FIG. 2 also shows (i) the parameter TdP/dT_max, which is the time to reach dP/dT_max, and (ii) the parameter AP at dP/dT_max, which is the arterial pressure at dP/dT_max.


Skewness is the third moment of the blood pressure wave (i.e., the degree to which the wave is asymmetric with respect to its mid-point). Skewness is illustrated in FIG. 4. (“RAS” refers to the renin-angiotensin system.)


Heart rate (HR) is the number of detected beats per minute.


Augmentation Index (AIx) is the ratio between irregular pressure waveform amplitude to the total pulse pressure, and is a measure of wave reflection and arterial stiffness. AIx is illustrated in FIG. 3.


Diastolic Decay Time Constant (or Diastolic Decay Constant) (D_tau) is exponential pressure decay time (RC) during the diastolic period. D_tau is illustrated in FIG. 2.


Diastolic Average Slope (Dslope) is the average of the pressure derivative during the diastolic phase.


Systolic Pressure (SP) is the maximal pressure point of the entire pressure wave. SP is illustrated in FIG. 2 as Systolic Arterial Pressure (SAP).


Systolic Average Slope (Sslope) is the average of the pressure derivative during the systolic phase.


Pulse Pressure (PP) is the difference between SP and diastolic pressure (minimal pressure during the entire pressure wave). PP is illustrated in FIG. 2.


Systolic Duration Ratio (SDR) is the duration of systole as a proportion of the entire pressure wave. SDR is illustrated in FIG. 2.


More details regarding the parameters are included in the table of FIGS. 1A-C.


Reference is now made to FIGS. 5-9, which are flow charts showing at least some steps in respective techniques for use with nerve tissue, in accordance with some applications of the invention. Typically, these techniques are performed transluminally, e.g., by advancing a catheter into the renal artery and applying excitatory current, and optionally ablation energy, to renal nerve tissue via the wall of the renal artery. For example, these techniques may be performed using a system 120 (described with reference to FIG. 10), and/or in combination with apparatus and/or techniques described in one or more of the following references, which are incorporated herein by reference:

    • PCT application publication WO 2014/068577 to Gross et al., filed Nov. 3, 2013, and entitled “Controlled Tissue Ablation,”
    • PCT application publication WO 2015/170281 to Gross et al., filed May 7, 2015, and entitled “Controlled Tissue Ablation Techniques,”
    • U.S. patent application Ser. No. 14/794,737 to Gross et al., filed Jul. 8, 2015, and entitled “Electrical Signal-Based Electrode-Tissue Contact Detection,” which published as US 2017/0007157,
    • U.S. patent application Ser. No. 14/972,756 to Gross et al., filed Dec. 17, 2015, and entitled “Transluminal Electrode Catheters,” which published as US 2017/0172651,
    • U.S. patent application Ser. No. 15/001,615 to Gross et al., filed Jan. 20, 2016, and entitled “Catheter Guidance and Procedure Planning,” which published as 2017/0202614.


As shown in FIG. 5, a method 20 is described, the method comprising: (i) applying an excitatory current to renal nerve fibers of a subject (box 24); (ii) determining a change in a parameter of the subject in response to the excitatory current (box 26), the parameter of the subject being a parameter that appears in the table of FIGS. 1A-C (and typically a parameter that appears in the top five in the table); (iii) in response to the change, deciding whether to ablate the renal nerve fibers (box 28); and (iv) in response to the deciding, applying ablation energy to the renal nerve fibers (box 30). Typically, the change in the parameter is determined by comparing a value of the parameter measured while the subject is at rest (e.g., before applying the excitatory current) (box 22) to a value measured during the application of the current (box 24).


For example, method 20, or a similar method, may be used to determine whether an individual subject is a suitable candidate for renal nerve ablation. Therefore, for some applications, a method comprises:

    • transluminally advancing a distal portion of a longitudinal member of a device into a renal artery of a subject;
    • operating the device to drive an electrode disposed on the distal portion of the longitudinal member to apply an excitatory current to nerve tissue of the renal artery;
    • receiving (i) a first value, the first value being indicative of a parameter of the subject (e.g., a parameter described herein) before a start of the application of the current, and (ii) a second value, the second value being indicative of the parameter of the subject after a start of the application of the current;
    • determining if a difference between the first value and the second value is smaller than a threshold difference; and
    • in response to the determining:
    • only if the determined difference is smaller than the threshold difference, withdrawing the longitudinal member from the subject without having applied ablation energy to the renal artery.


For some applications, instead of withdrawing the longitudinal member from the subject, the longitudinal member is moved to another site within the subject and the process is repeated. For some applications, following several iterations of the process, if the determined difference at more than a threshold proportion of the sites (e.g., more than 50 percent, e.g., more than 60 percent, e.g., more than 70 percent, e.g., more than 80 percent, e.g., more than 90 percent) is smaller than the threshold difference, the longitudinal member is withdrawn from the subject without having applied ablation energy to the renal artery.


For some applications, method 20 is used at various locations within the renal artery, mutatis mutandis, e.g., to locate target renal nerve tissue (and optionally ablate it). Therefore, as shown in FIG. 6, a method 40 is described, the method being the same as method 20, wherein: (a) applying the excitatory current (box 24 of FIG. 5) comprises applying the excitatory current to renal nerve fibers proximate to a first location of a renal artery wall (box 42), (b) deciding whether to ablate the renal nerve fibers (box 28 of FIG. 5) comprises deciding whether to ablate the renal nerve fibers proximate to the first location (box 50), and (c) the method further comprises: (i) applying the excitatory current to renal nerve fibers proximate to a second location of a renal artery wall (box 46); (ii) determining a second change in the parameter in response to the excitatory current applied to the renal nerve fibers proximate to the second location (box 48); and (iii) in response to the second change, deciding whether to ablate the renal nerve fibers proximate to the second location (box 50). In response to deciding whether to ablate the renal nerve fibers proximate to the first location or the second location, ablation energy is applied to the renal nerve fibers (box 52). Box 44 of FIG. 6 corresponds to box 26 of FIG. 5 in the same way that boxes 42 and 50 of FIG. 6 correspond to boxes 24 and 28 of FIG. 5, respectively.


For some applications, a modality of ablation is selected in response to the change in value of the parameter. For example, the modality may be selected from radiofrequency (RF), ultrasound, heating, cooling, laser, chemical, or any other ablation modality known in the art. Therefore, as shown in FIG. 7, a method 60 is described, the method comprising (i) applying an excitatory current to renal nerve fibers of a subject (box 62); (ii) determining a change in a parameter of the subject in response to the excitatory current (box 64), the parameter of the subject being a parameter that appears in the table of FIGS. 1A-C (and typically a parameter that appears in the top five in the table); (iii) in response to the change, selecting an ablation modality from a plurality of ablation modalities (66); and (iv) in response to the selecting, ablating the renal nerve fibers using the selected ablation modality (box 68).


For some applications, the parameters in the table of FIGS. 1A-C are used to monitor the progress of an ablation process. For example, ablation energy may be applied to the nerve tissue iteratively, and measurement of the parameter after each application may be used to determine whether the nerve tissue has become sufficiently ablated (e.g., sufficiently unable to propagate action potentials therealong). Therefore, as shown in FIG. 8, a method is described, the method comprising: (i) applying an application of excitatory current to renal nerve fibers of a subject (box 82); (ii) determining a first change in a parameter of the subject in response to the application of excitatory current (box 84), the parameter of the subject being a parameter that appears in the table of FIGS. 1A-C (and typically a parameter that appears in the top five in the table); (iii) subsequently, applying a first application of ablating energy to the renal nerve fibers (box 86); (iv) subsequently, applying another application of excitatory current to renal nerve fibers of a subject (box 88); (v) determining a second change in the parameter in response to the second application of excitatory current (box 90); (vi) determining a difference between the first change and the second change (box 92); (vii) deciding whether to apply a second application of ablation energy to the renal nerve fibers (box 94); and (viii) in response to the deciding, applying the second application of ablation energy to the renal nerve fibers (box 96).


Because, as described hereinabove and in the table of FIGS. 1A-C, the parameters relate to different physiological aspects (e.g., properties), it is hypothesized that determining how the parameters respond to excitation of renal nerve tissue may facilitate more detailed understanding and/or definition of the particular condition of the subject (e.g., enabling a more specific diagnosis of the condition). It is further hypothesized that taking into account two or more of the parameters will be further facilitative. As shown in FIG. 9, a method 100 is described, the method comprising: (i) transluminally advancing an electrode into a renal artery of a subject; (ii) while the subject is at rest, measuring a first value of a first parameter (box 102) and a first value of a second parameter (box 104), the first parameter and the second parameter selected from the parameters that appear in the table of FIGS. 1A-C (and typically those that appear in the top five in the table); (iii) applying an excitatory current to renal nerve fibers of a subject, and while applying the excitatory current, measuring a second value of the first parameter and a second value of the second parameter (box 106); (iv) determining (a) a first difference between the first value of the first parameter and the second value of the first parameter, and (b) a second difference between the first value of the second parameter and the second value of the second parameter (box 108); and (v) in response to the first difference and the second difference, diagnosing a pathology of the subject (110).


For some applications, differences between first and second values of only two parameters from the table are used for diagnosing the pathology (e.g., the first and second parameters in the above paragraph). For some applications more than two parameters (e.g., at least three parameters, e.g., at least four parameters, such as at least five parameters) from the table (and typically from the top five in the table) are used.


Reference is again made to FIGS. 1A-8. Although methods 20, 40, 60, and 80 are generally described with reference to “a parameter,” it is to be understood that the scope of the invention includes the use of more than one of the parameters in the table of FIGS. 1A-C (typically in the top five parameters of the table). Furthermore, methods 20, 40, 60, 80, and 100 may be further facilitated by taking into account other parameters of the subject, including other blood pressure parameters, and non-blood pressure parameters.


Reference is again made to FIGS. 1A-9. Described hereinabove are parameter values measured before application of the excitatory current, and parameter values measured during application of the excitatory current. It is to be noted that for some applications of the invention, the timing of these two measurements may differ from a strict definition of these timings, in that, for example, a “before” value of the parameter may be measured soon after the beginning of application of the excitatory current, before the action potentials initiated by the excitatory current have begun to affect the parameter. Similarly, a “during” value of the parameter may be measured soon after the end of application of the excitatory current, before the parameter has begun to return toward the “before” value.


Reference is again made to FIGS. 1A-9. The excitatory current described hereinabove is to be understood as a current that initiates action potentials in the nerve tissue. Typically, the excitatory current has a frequency of greater than 1 Hz and/or less than 100 Hz, such as between 1 and 100 Hz, e.g., between 10 and 100 Hz. For some applications, the ablation energy described hereinabove is RF energy, e.g., an RF current having a frequency of above 5 kHz and/or below 1 GHz, such as between 5 kHz and 1 GHz (e.g., 10 kHz-10 MHz, e.g., 50 kHz-1 MHz, e.g., 300 kHz-1 MHz, e.g., 300 kHz-500 kHz).


Reference is again made to FIGS. 5-9. For some applications, the techniques described hereinabove are performed generally manually by a physician (alone, or with assistance). For example, a commercially-available arterial blood pressure sensor may be used to monitor arterial blood pressure; the output may be separately analyzed (e.g., manually, or using a computer) to measure the values of the parameter(s); and the change in the value of the parameter(s) may be separately determined (e.g., manually, or using a computer).


Reference is now made to FIG. 10, which is a schematic illustration of a system 120 for ablating and/or stimulating nerve tissue of a blood vessel of a subject, such as a renal artery 10, in accordance with some applications of the present invention. For some applications, the techniques described hereinabove are performed generally automatically by a device such as system 120, comprising a transluminal electrode catheter 122 that comprises a transluminally-advanceable longitudinal member (e.g., a flexible shaft) 124, one or more electrodes 126 at a distal portion 128 of the longitudinal member, and a (typically extracorporeal) control unit 130 that comprises control circuitry 132, and is electrically coupled to the catheter. Control unit 130 is typically a programmed digital computing device comprising a central processing unit (CPU), random access memory (RAM), non-volatile secondary storage, such as a hard drive or CD ROM drive, network interfaces, and/or peripheral devices. Program code, including software programs, and/or data are loaded into the RAM for execution and processing by the CPU and results are generated for display, output, transmittal, or storage, as is known in the art. Such program code and/or data, when provided to the control unit, produce a machine or special-purpose computer, configured to perform the tasks described herein. Typically, control unit 130 is connected to an arterial blood pressure sensor 132 (which may be disposed on longitudinal member 124), and is configured to receive signals from the sensor.


Typically, control unit 30 comprises a user interface 134, which is configured to receive user input (e.g., activation of the system) and/or to output measurements and/or status.


The control unit automatically performs one or more of the following steps: (1) deriving the value of the parameter (e.g., from raw pressure data from the pressure sensor), (2) driving the electrodes to apply the excitatory current, (3) determining a change in the parameter value in response to the excitatory current, and (4) providing an output via an interface. For some applications, the output indicates the change in the parameter value in response to the excitatory current (e.g., as an absolute value, as a relative value, or as an indication of whether the change exceeds a threshold change), and based on the output the physician decides whether to ablate.


For some applications, the control unit drives the electrodes to apply the ablation energy, either automatically in response to the determined change in the parameter value, or when activated by the physician. That is, for some applications, the same device is configured and used to apply the excitatory current and to apply the ablation energy (and typically to measure the arterial blood pressure). For some applications, the device is not configured or used to apply both the excitatory current and the ablation energy. For example, a separate ablation device may be used, either during the same general procedure (e.g., without the subject leaving the treatment room), or at another time.


Therefore, for some applications, apparatus comprises:

    • a transluminal electrode catheter 122, comprising:
      • a flexible shaft 124, dimensioned for advancement of a distal portion 128 of the shaft into a renal artery 10 of a subject;
      • a plurality of electrodes 126 disposed at the distal portion of the shaft; and
      • an arterial blood pressure sensor 132; and
    • a control unit 130, electrically coupled to the catheter.


For some applications, control unit 130 is configured to:

    • use sensor 124 to measure a first value of a parameter of the subject while the subject is at rest (the parameter being a parameter described herein),
    • drive at least one of the electrodes 126 to apply an excitatory current to renal nerve fibers of the subject,
    • while applying the excitatory current, use the blood pressure sensor to measure a second value of the parameter,
    • determine if a difference between the first value and the second value is greater than a threshold difference, and
    • in response to the determining:
      • only if the determined difference is greater than the threshold difference, enable an ablation function of the control unit.


The ablation function of control unit 130 can be activated only while enabled. Upon its activation, the ablation function of the control unit drives at least one of the electrodes to apply ablation energy to the renal nerve fibers (through the wall of renal artery 10). For some applications, control unit 130 activates the ablation function automatically upon the enabling of the ablation function. For some applications, control unit enables the ablation function, but activation of the ablation function requires subsequent user input (e.g., via interface 134).


For some applications, the devices described hereinabove are similar to those described in PCT application publication WO 2014/068577 to Gross et al., filed Nov. 3, 2013, and entitled “Controlled Tissue Ablation,” and/or a PCT application to Yossi GROSS et al., filed on even date herewith, and entitled “Controlled Tissue Ablation Techniques,” both of which are incorporated herein by reference.


It will be understood that, although the terms “first,” “second,” etc. may be used in the present application (including the specification and the claims) to describe various elements and/or directions, these terms should not be limiting. These terms are only used to distinguish one element and/or direction from another. Thus, a “first” element described herein could also be termed a “second” element without departing from the teachings of the present disclosure.


It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Claims
  • 1. A method, comprising: applying an excitatory current to renal nerve fibers of a subject;determining a change in a parameter of the subject in response to the excitatory current, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject;in response to the change, deciding whether to ablate or to not ablate the renal nerve fibers; andin response to a decision to ablate, applying ablation energy to the renal nerve fibers.
  • 2. The method according to claim 1, wherein: the renal nerve fibers comprise renal nerve fibers proximate to a first location of a renal artery wall and renal nerve fibers proximate to a second location of the renal artery wall;applying the excitatory current comprises applying the excitatory current to the renal nerve fibers proximate to the first location of the renal artery wall, deciding whether to ablate or to not ablate the renal nerve fibers comprises deciding whether to ablate or to not ablate the renal nerve fibers proximate to the first location of the renal artery wall, andthe method further comprises:applying the excitatory current to the renal nerve fibers proximate to the second location of the renal artery wall;determining a second change in the parameter in response to the excitatory current applied to the renal nerve fibers proximate to the second location of the renal artery wall; andin response to the second change, making a second decision to ablate or to not ablate the renal nerve fibers proximate to the second location of the renal artery wall.
  • 3. A method, comprising: measuring a first value of a parameter of a subject while the subject is at rest, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject;applying an excitatory current to renal nerve fibers of the subject;while applying the excitatory current, measuring a second value of the parameter;in response to a difference between the first value and the second value, deciding whether to ablate or to not ablate the renal nerve fibers; andin response to a decision to ablate, applying ablation energy to the renal nerve fibers.
  • 4. A method, comprising: applying an excitatory current to renal nerve fibers of a subject;determining a change in a parameter of the subject in response to the excitatory current, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject;in response to the change, selecting an ablation modality from a plurality of ablation modalities; andin response to the selecting, ablating the renal nerve fibers using the selected ablation modality.
  • 5. A method, comprising: applying a first application of excitatory current to renal nerve fibers of a subject;determining a first change in a parameter of the subject in response to the first application of excitatory current, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject;subsequently, applying a first application of ablation energy to the renal nerve fibers;subsequently, applying a second application of excitatory current to the renal nerve fibers of the subject;determining a second change in the parameter in response to the second application of excitatory current;determining a difference between the first change and the second change;deciding whether to apply or to not apply a second application of ablation energy to the renal nerve fibers; andin response to a decision to apply the second application of ablation energy, applying the second application of ablation energy to the renal nerve fibers.
  • 6. A method, comprising: transluminally advancing a distal portion of a longitudinal member of a device into a renal artery of a subject;operating the device to drive an electrode disposed on the distal portion of the longitudinal member to apply an excitatory current to nerve tissue of the renal artery;receiving (i) a first value, the first value being indicative of a parameter of the subject before a start of the application of the excitatory current, and (ii) a second value, the second value being indicative of the parameter of the subject after the start of the application of the excitatory current, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject;determining if a difference between the first value and the second value is smaller than a threshold difference; andin response to the determining:only if the determined difference is smaller than the threshold difference, withdrawing the longitudinal member from the subject without having applied ablation energy to the renal artery.
  • 7. Apparatus comprising: a transluminal electrode catheter, comprising:a flexible shaft, dimensioned for advancement of a distal portion of the shaft into a renal artery of a subject;a plurality of electrodes disposed at the distal portion of the shaft;an arterial blood pressure sensor; anda control unit, electrically coupled to the catheter, and configured to:use the arterial blood pressure sensor to measure a first value of a parameter of the subject while the subject is at rest, the parameter being a fastest rate of increase in arterial pressure during a systolic upstroke of an arterial pressure wave of the subject, drive at least one of the electrodes to apply an excitatory current to renal nerve fibers of the subject, while applying the excitatory current, use the arterial blood pressure sensor to measure a second value of the parameter, determine if a difference between the first value and the second value is greater than a threshold difference, andin response to the determining:only if the determined difference is greater than the threshold difference, enable an ablation function of the control unit and drive at least one of the electrodes to apply ablation energy to the renal nerve fibers.
CROSS-REFERENCES TO RELATED APPLICATIONS

The present application claims the benefit of U.S. Provisional Application 62/158,139 to Gross et al., filed May 7, 2015, and entitled “Techniques for use with nerve tissue,” which is incorporated herein by reference.

US Referenced Citations (329)
Number Name Date Kind
4106488 Gordon Aug 1978 A
4569836 Gordon Feb 1986 A
4619247 Inoue Oct 1986 A
5215086 Terry, Jr. et al. Jun 1993 A
5251634 Weinberg Oct 1993 A
5697377 Wittkampf Dec 1997 A
5735280 Sherman et al. Apr 1998 A
5776063 Dittrich et al. Jul 1998 A
5807285 Vaitekunas Sep 1998 A
5817022 Vesely Oct 1998 A
5827216 Igo et al. Oct 1998 A
6050943 Slayton Apr 2000 A
6064902 Haissaguerre et al. May 2000 A
6117101 Diederich Sep 2000 A
6128523 Bechtold Oct 2000 A
6161048 Sluijter Dec 2000 A
6219577 Brown Apr 2001 B1
6233477 Chia May 2001 B1
6241727 Tu Jun 2001 B1
6246899 Chia Jun 2001 B1
6361500 Masters Mar 2002 B1
6405732 Edwards Jun 2002 B1
6425877 Edwards Jul 2002 B1
6440077 Jung Aug 2002 B1
6485431 Campbell Nov 2002 B1
6522926 Kieval Feb 2003 B1
6526318 Ansarinia Feb 2003 B1
6605084 Acker et al. Aug 2003 B2
6635054 Fjield et al. Oct 2003 B2
6641579 Bernardi Nov 2003 B1
6659950 Taheri Dec 2003 B2
6671556 Osorio et al. Dec 2003 B2
6684105 Cohen et al. Jan 2004 B2
6685639 Wang Feb 2004 B1
6692490 Edwards Feb 2004 B1
6701931 Sliwa et al. Mar 2004 B2
6736835 Pellegrino May 2004 B2
6740040 Mandrusov May 2004 B1
6805129 Pless et al. Oct 2004 B1
6845267 Harrison Jan 2005 B2
7001336 Mandrusov Feb 2006 B2
7022105 Edwards Apr 2006 B1
7037306 Podany et al. May 2006 B2
7149574 Yun Dec 2006 B2
7162303 Levin Jan 2007 B2
7226440 Gelfand et al. Jun 2007 B2
7311701 Gifford et al. Dec 2007 B2
7326201 Fjield et al. Feb 2008 B2
7430449 Aldrich Sep 2008 B2
7499747 Kieval Mar 2009 B2
7510536 Foley Mar 2009 B2
7553284 Vaitekunas Jun 2009 B2
7565191 Burbank et al. Jul 2009 B2
7617005 Demarais Nov 2009 B2
7647115 Levin et al. Jan 2010 B2
7653438 Deem Jan 2010 B2
7662099 Podany et al. Feb 2010 B2
7684865 Aldrich Mar 2010 B2
7706882 Francischelli Apr 2010 B2
7717948 Demarais May 2010 B2
7787946 Stahmann et al. Aug 2010 B2
7840271 Kieval Nov 2010 B2
7853333 Demarais Dec 2010 B2
7854733 Govari Dec 2010 B2
7901359 Mandrusov Mar 2011 B2
7974696 DiLorenzo Jul 2011 B1
8197409 Foley Jun 2012 B2
8391970 Tracey et al. Mar 2013 B2
8585601 Sverdlik et al. Nov 2013 B2
8696581 Sverdlik et al. Apr 2014 B2
8702619 Wang Apr 2014 B2
9014821 Wang Apr 2015 B2
9028417 Sverdlik et al. May 2015 B2
9381063 Gang et al. Jul 2016 B2
9408549 Brockway et al. Aug 2016 B2
9439598 Shimada et al. Sep 2016 B2
9566456 Sverdlik et al. Feb 2017 B2
9999463 Puryear et al. Jun 2018 B2
20010003798 McGovern Jun 2001 A1
20010007940 Tu Jul 2001 A1
20020091427 Rappaport Jul 2002 A1
20020147446 Ein-Gal Oct 2002 A1
20020173688 Chen Nov 2002 A1
20020193787 Qin et al. Dec 2002 A1
20030018256 Sasaki Jan 2003 A1
20030045909 Gross et al. Mar 2003 A1
20030055421 West Mar 2003 A1
20030069590 Rabiner Apr 2003 A1
20030013968 Fjield Jun 2003 A1
20040034339 Stoller Feb 2004 A1
20040038857 Tracey Feb 2004 A1
20040097788 Mourlas May 2004 A1
20040122494 Eggers et al. Jun 2004 A1
20040162507 Govari et al. Aug 2004 A1
20040162550 Govari et al. Aug 2004 A1
20040193021 Savage Sep 2004 A1
20050020921 Glassell Jan 2005 A1
20050080469 Larson et al. Apr 2005 A1
20050165298 Larson Jul 2005 A1
20050192638 Gelfand Sep 2005 A1
20050203410 Jenkins Sep 2005 A1
20050222554 Wallace et al. Oct 2005 A1
20050251125 Pless Nov 2005 A1
20050288651 Van Tassel et al. Dec 2005 A1
20050288730 Deem et al. Dec 2005 A1
20060009753 Fjield et al. Jan 2006 A1
20060041277 Deem Feb 2006 A1
20060058711 Harhen et al. Mar 2006 A1
20060100514 Lopath May 2006 A1
20060184048 Saadat Aug 2006 A1
20060206150 Demarais Sep 2006 A1
20060212076 Demarais Sep 2006 A1
20060212078 Demarais Sep 2006 A1
20060241523 Sinelnikov et al. Oct 2006 A1
20060265014 Demarais Nov 2006 A1
20060265015 Demarais Nov 2006 A1
20060271111 Demarais Nov 2006 A1
20060276852 Demarais Dec 2006 A1
20060287648 Schwartz Dec 2006 A1
20070004984 Crum et al. Jan 2007 A1
20070021803 Deem Jan 2007 A1
20070038259 Kieval Feb 2007 A1
20070060972 Kieval Mar 2007 A1
20070093420 Yeomans Apr 2007 A1
20070112327 Lee May 2007 A1
20070129760 Demarais Jun 2007 A1
20070129761 Demarais Jun 2007 A1
20070133849 Young et al. Jun 2007 A1
20070135875 Demarais Jun 2007 A1
20070142879 Greenberg Jun 2007 A1
20070162085 DiLorenzo Jun 2007 A1
20070167984 Kieval Jun 2007 A1
20070167913 Elkins et al. Jul 2007 A1
20070173899 Levin et al. Jul 2007 A1
20070191906 Caparso Aug 2007 A1
20070203549 Demarais Aug 2007 A1
20070239077 Azhari et al. Oct 2007 A1
20070265610 Thapliyal et al. Nov 2007 A1
20070265687 Deem Nov 2007 A1
20070282407 Demarais Dec 2007 A1
20080004614 Burdette Jan 2008 A1
20080015445 Saadat Jan 2008 A1
20080033415 Rieker et al. Feb 2008 A1
20080039746 Francischelli Feb 2008 A1
20080058682 Azhari et al. Mar 2008 A1
20080058702 Arndt Mar 2008 A1
20080071173 Aldrich Mar 2008 A1
20080091109 Abraham Apr 2008 A1
20080108984 Burdette May 2008 A1
20080125819 Ben-David et al. May 2008 A1
20080140180 Dolan et al. Jun 2008 A1
20080172104 Kieval Jul 2008 A1
20080183248 Rezai Jul 2008 A1
20080215111 Kieval Sep 2008 A1
20080255449 Sinelnikov Oct 2008 A1
20080255642 Zarins Oct 2008 A1
20080281379 Wesselink Nov 2008 A1
20080288017 Kieval Nov 2008 A1
20080288031 Kieval Nov 2008 A1
20080306570 Rezai Dec 2008 A1
20080312521 Solomon Dec 2008 A1
20080319513 Pu Dec 2008 A1
20090024195 Rezai et al. Jan 2009 A1
20090048514 Azhari Feb 2009 A1
20090062790 Malchano Mar 2009 A1
20090062873 Wu et al. Mar 2009 A1
20090076409 Wu Mar 2009 A1
20090112133 Deisseroth Apr 2009 A1
20090118780 DiLorenzo May 2009 A1
20090137900 Bonner et al. May 2009 A1
20090155336 Rezai Jun 2009 A1
20090187230 DiLorenzo Jun 2009 A1
20090192506 Vaska et al. Jul 2009 A9
20090234407 Hastings et al. Sep 2009 A1
20090247912 Warnking Oct 2009 A1
20090270741 Vanney et al. Oct 2009 A1
20090275827 Aiken et al. Nov 2009 A1
20090287274 Ridder Nov 2009 A1
20090326511 Shivkumar Dec 2009 A1
20100004704 Mazgalev Jan 2010 A1
20100010567 Deem Jan 2010 A1
20100036292 Darlington et al. Feb 2010 A1
20100042170 Caparso Feb 2010 A1
20100105993 Hassan Apr 2010 A1
20100113928 Thapliyal May 2010 A1
20100130836 Malchano May 2010 A1
20100137860 Demarais Jun 2010 A1
20100137949 Mazgalev Jun 2010 A1
20100137952 Demarais et al. Jun 2010 A1
20100145428 Cameron Jun 2010 A1
20100168624 Sliwa Jul 2010 A1
20100168731 Wu et al. Jul 2010 A1
20100168739 Wu et al. Jul 2010 A1
20100174282 Demarais Jul 2010 A1
20100191112 Demarais Jul 2010 A1
20100204741 Tweden Aug 2010 A1
20100217162 Francischelli Aug 2010 A1
20100217369 Gross Aug 2010 A1
20100222851 Deem Sep 2010 A1
20100222854 Demarais Sep 2010 A1
20100234728 Foley Sep 2010 A1
20100256436 Partsch Oct 2010 A1
20100268297 Neisz Oct 2010 A1
20100305392 Gross et al. Dec 2010 A1
20100312094 Guttman et al. Dec 2010 A1
20110009734 Foley Jan 2011 A1
20110015548 Aldrich Jan 2011 A1
20110022133 Bradford Jan 2011 A1
20110040171 Foley Feb 2011 A1
20110040214 Foley Feb 2011 A1
20110060324 Wu Mar 2011 A1
20110092781 Gertner Apr 2011 A1
20110092880 Gertner Apr 2011 A1
20110112394 Mishelevich May 2011 A1
20110112400 Emery May 2011 A1
20110118598 Gertner May 2011 A1
20110118600 Gertner May 2011 A1
20110118725 Mayse May 2011 A1
20110137149 Gertner Jun 2011 A1
20110137298 Chen Jun 2011 A1
20110172527 Gertner Jun 2011 A1
20110172528 Gertner Jun 2011 A1
20110172529 Gertner Jun 2011 A1
20110178570 Demarais Jun 2011 A1
20110184337 Evans Jun 2011 A1
20110178541 Azhari Jul 2011 A1
20110184322 Brawer Jul 2011 A1
20110196248 Grunwald Aug 2011 A1
20110207758 Sobotka et al. Aug 2011 A1
20110208173 Sobotka et al. Aug 2011 A1
20110208175 Sobotka et al. Aug 2011 A1
20110251524 Azhari Oct 2011 A1
20110257523 Hastings et al. Oct 2011 A1
20110257564 Demarais et al. Oct 2011 A1
20110257641 Hastings et al. Oct 2011 A1
20110264075 Leung et al. Oct 2011 A1
20110264086 Ingle Oct 2011 A1
20110264116 Kocur et al. Oct 2011 A1
20110282203 Tsoref Nov 2011 A1
20110282249 Tsoref Nov 2011 A1
20110306851 Wang Dec 2011 A1
20120029500 Jenson Feb 2012 A1
20120029505 Jenson Feb 2012 A1
20120029509 Smith et al. Feb 2012 A1
20120029510 Haverkost Feb 2012 A1
20120029511 Smith et al. Feb 2012 A1
20120029512 Willard et al. Feb 2012 A1
20120029513 Smith et al. Feb 2012 A1
20120089047 Ryba et al. Apr 2012 A1
20120095371 Sverdlik et al. Apr 2012 A1
20120101413 Beetel et al. Apr 2012 A1
20120101538 Ballakur et al. Apr 2012 A1
20120116382 Ku et al. May 2012 A1
20120130363 Kim May 2012 A1
20120150049 Zielinski et al. Jun 2012 A1
20120157992 Smith et al. Jun 2012 A1
20120172680 Gelfand et al. Jul 2012 A1
20120191079 Moll et al. Jul 2012 A1
20120197198 Demarais Aug 2012 A1
20120197243 Sherman et al. Aug 2012 A1
20120265198 Crow et al. Oct 2012 A1
20120265227 Sverdlik et al. Oct 2012 A1
20120290024 Zhang et al. Nov 2012 A1
20120296240 Azhari Nov 2012 A1
20120296329 Ng Nov 2012 A1
20130012866 Deem Jan 2013 A1
20130013024 Levin Jan 2013 A1
20130085489 Fain et al. Apr 2013 A1
20130103028 Tsoref Apr 2013 A1
20130131743 Yamasaki et al. May 2013 A1
20130165926 Mathur Jun 2013 A1
20130204242 Sverdlik et al. Aug 2013 A1
20130211396 Sverdlik et al. Aug 2013 A1
20130211437 Sverdlik et al. Aug 2013 A1
20130218029 Cholette et al. Aug 2013 A1
20130218054 Sverdlik et al. Aug 2013 A1
20130218068 Sverdlik et al. Aug 2013 A1
20130231655 Budzelaar et al. Sep 2013 A1
20130274614 Shimada Oct 2013 A1
20130274735 Hastings et al. Oct 2013 A1
20130289369 Margolis Oct 2013 A1
20130303876 Gelfand et al. Nov 2013 A1
20130310674 Deno et al. Nov 2013 A1
20130310823 Gelfand et al. Nov 2013 A1
20130322724 Florent et al. Dec 2013 A1
20130324987 Leung et al. Dec 2013 A1
20130324989 Leung et al. Dec 2013 A1
20130331813 Barbut et al. Dec 2013 A1
20140005706 Gelfand et al. Jan 2014 A1
20140012133 Sverdlik et al. Jan 2014 A1
20140018788 Engelman et al. Jan 2014 A1
20140088561 Levin et al. Mar 2014 A1
20140128865 Gross May 2014 A1
20140194866 Wang Jul 2014 A1
20140213873 Wang Jul 2014 A1
20140221805 Wang Aug 2014 A1
20140243809 Gelfand et al. Aug 2014 A1
20140257263 Azamian et al. Sep 2014 A1
20140276036 Collins et al. Sep 2014 A1
20140276063 Park et al. Sep 2014 A1
20140276742 Nabutovsky et al. Sep 2014 A1
20140288551 Bharmi et al. Sep 2014 A1
20150011843 Toth et al. Jan 2015 A1
20150045649 O'Dea et al. Feb 2015 A1
20150073400 Sverdlik et al. Mar 2015 A1
20150148601 Weiner et al. May 2015 A1
20150164401 Toth et al. Jun 2015 A1
20150173673 Toth et al. Jun 2015 A1
20150216590 Wang et al. Aug 2015 A1
20150224326 Toth et al. Aug 2015 A1
20150245867 Gross Sep 2015 A1
20150257779 Sinelnikov et al. Sep 2015 A1
20150289929 Toth et al. Oct 2015 A1
20150297113 Kassab et al. Oct 2015 A1
20150297139 Toth Oct 2015 A1
20160000499 Lennox et al. Jan 2016 A1
20160106498 Highsmith et al. Apr 2016 A1
20160113699 Sverdlik et al. Apr 2016 A1
20160128767 Azamian et al. May 2016 A1
20160324572 Gross et al. Nov 2016 A1
20160338773 Shimada et al. Nov 2016 A1
20170007157 Gross et al. Jan 2017 A1
20170007158 Gross et al. Jan 2017 A1
20170027460 Shimada et al. Feb 2017 A1
20170035310 Shimada et al. Feb 2017 A1
20170056104 Asirvatham Mar 2017 A1
20170172651 Gross et al. Jun 2017 A1
20180221087 Puryear et al. Aug 2018 A1
20180280082 Puryear et al. Oct 2018 A1
Foreign Referenced Citations (33)
Number Date Country
2900160 Aug 2014 CA
2956945 Feb 2016 CA
102551878 Jul 2012 CN
203089369 Jul 2013 CN
2460486 Jun 2012 EP
199940957 Aug 1999 WO
03097162 Nov 2003 WO
2006072928 Jul 2006 WO
07134258 Nov 2007 WO
2008003058 Jan 2008 WO
2009073208 Jun 2009 WO
2010067360 Jun 2010 WO
2011024159 Mar 2011 WO
2011141918 Nov 2011 WO
2012100211 Jul 2012 WO
2012120495 Sep 2012 WO
2012122157 Sep 2012 WO
2013030738 Mar 2013 WO
2013030743 Mar 2013 WO
2013049601 Apr 2013 WO
2013111136 Aug 2013 WO
2013121424 Aug 2013 WO
2013157009 Oct 2013 WO
2014029355 Feb 2014 WO
2014068577 May 2014 WO
2014071223 May 2014 WO
2014123512 Aug 2014 WO
2014160832 Oct 2014 WO
2014175853 Oct 2014 WO
2015057696 Apr 2015 WO
2015138225 Sep 2015 WO
2015170281 Nov 2015 WO
2015175948 Nov 2015 WO
Non-Patent Literature Citations (143)
Entry
Buch E et al., “Intra-pericardial balloon retraction of the left atrium: A novel method to prevent esophageal injury during catheter ablation,” Heart Rhythm 2008;5:1473-1475.
Cassak D, “Endosense: Facing technology and financing challenges in AF,” In-Vivo: The Business & Medicine Report, 36-44, Mar. 2010.
Di Biase L et al., “Prevention of phrenic nerve injury during epicardial ablation: Comparison of methods for separating the phrenic nerve from the epicardial surface,” Heart Rhythm 2009;6:957-961.
Matsuo S et al., “Novel technique to prevent left phrenic nerve injury during epicardial catheter ablation,” Circulation 2008;117;e471.
Nakahara S et al., “Intrapericardial balloon placement for prevention of collateral injury during catheter ablation of the left atrium in a porcine model,” Heart Rhythm 2010;7:81-87.
Shen J et al., “The surgical treatment of atrial fibrillation Heart Rhythm,” vol. 6, No. 8S, August Supplement 2009.
Sacher F et al., “Phrenic Nerve Injury After Catheter Ablation of Atrial Fibrillation,” Indian Pacing Electrophysiol J. Jan.- Mar. 2007; 7(1): 1-6.
A Restriction Requirement dated Feb. 25, 2013, which issued during the prosecution of U.S. Appl. No. 12/780,240.
Tanaka S et al., “Development of a new vascular endoscopic system for observing inner wall of aorta using intermittent saline jet” World Congress on Medical Physics and Biomedical Engineering, Sep. 7-12, 2009, Munich, Germany.
Tearney GJ et al., “Three-Dimensional coronary artery microscopy by intracoronary optical frequency domain imaging” JACC Cardiovasc Imaging. Nov. 2008; 1(6): 752-761.
An Office Action dated Aug. 21, 2015, which issued during the prosecution of U.S. Appl. No. 13/771,853.
William E. Cohn, et al., “Contrast pericardiography facilitates intrapericardial navigation under fluoroscopy”, Ann Thorac Surg 2010; 90: 1537-40. Accepted for publication Jun. 7, 2010.
Srijoy Mahapatra, et al., “Pressure frequency characteristics of the pericardial space and thorax during subxiphoid access for epicardial ventricular tachycardia ablation”, Heart Rhythm 2010; 7:604-609.
Schuessler RB et al., “Animal studies of epicardial atrial ablation,” Heart Rhythm, vol. 6, No. 12S, S41-S45 December Supplement 2009.
An International Search Report and a Written Opinion both dated Oct. 26, 2011, which issued during the prosecution of Applicant's PCT/IL11/00382.
An International Search Report and a Written Opinion both dated Sep. 17, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000100.
An International Preliminary Report on Patentability dated Nov. 20, 2012, which issued during the prosecution of Applicant's PCT/IL11/00382.
An International Search Report dated Jul. 31, 2008, which issued during the prosecution of Applicant's PCT/US07/68818.
An Office Action dated Dec. 20, 2012, which issued during the prosecution of U.S. Appl. No. 11/653,115.
An Office Action dated Feb. 19, 2013, which issued during the prosecution of U.S. Appl. No. 13/010,555.
Fajardo et al., Effects of Hyperthermia in a Maligant Tumor, Cancer 45:613-623 (1980).
Short et al., Physical Hyperthermia and Cancer Therapy, Proceedings of the IEEE 68:133-142 (1980) p. 136, col. 2, para 6.
U.S. Appl. No. 60/370,190, filed Apr. 8, 2002.
U.S. Appl. No. 60/307,124, filed Jul. 23, 2001.
An Office Action dated May 17, 2013, which issued during the prosecution of U.S. Appl. No. 12/780,240.
An Invitation to pay additional fees dated Jun. 7, 2013, which issued during the prosecution of Applicant's PCT/IL2013/050134.
An International Search Report and a Written Opinion both dated Aug. 12, 2013 which issued during the prosecution of Applicant's PCT/IL2013/050134.
An International Search Report and a Written Opinion both dated Feb. 18, 2011 which issued during the prosecution of Applicant's PCT/IL2010/000683.
An International Preliminary Report of patentability dated Feb. 28, 2012 which issued during the prosecution of Applicant's PCT/IL2010/000683.
F. Mahfoud et al., Catherter-Based renal denervation increases insulin sensitivity and improves glucose metabolism. European Heart Journal 2010.
F. Mahfoud et al., Effects of Renal Sympathetic Denervation on Glucose Metabolism in Patients with Resistant Hypertension: A Pilot Study. Circulation 2011: 123 1940-1946.
Tai et al., Analysis of Nerve Conduction Including by Direct Current, J Comput Neuro. Published Online on 2009.
Ariav et al., Electrical Stimulation Induced Relaxation of Isolated Pig Aortas, Scientific Sessions 2011. American Heart Association.Abstract.
Stella et al., Cardiovascular Effects of Efferent renal nerve stimulation, Clin and Exper. Theory and Practice, 97-111, 1987.
Mortimer and Bhadra., Peripheral Nerve and Muscle Stimulation, Chapter 4.2, 1-48, 2004.
Stella et al., Effects of afferent renal nerve stimulation on renal hemodynamic and excretory functions, American Journal of physiology, 576-583, 1984.
Renal Sympathetic denervation in patients with treatment resistant hypertension, (1-7) Published online Nov. 2010.
Zhang et al., Mechanism of Nerve conduction Block induced by High-Frequency Biphasic Electrical Currents, IEEE Biomedical Engineering vol. 53 No. 12, 2006.
Bhadra et al., Reduction of the Onset Response in High-Frequency Nerve Block with Amplitude Ramps from Non-Zero Amplitudes, 650-653, 2009 IEEE.
Tai et al., Stimulation of Nerve Block by High-Frequency Sinusoidal Electrical Current Based on the Hodgkin-Huxley Model, IEEE Neural Systems and Rehabilitation engineering, vol. 13 No. 3, 2005.
Tsui, Electrical Nerve Stimulation, Springer Atlas of Ultrasound, pp. 9-18, 2008.
Bartus et al., Denervation (ablation) of Nerve Terminalis in renal arteries: early results of interventional treatment of arterial hypertension in Poland, Kardiologia Polska 2013, 71, 2: 152-158.
Krum et al., Catherter-Based Renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study, Lancet 2009.
Chinushi M. et al., Blood pressure and autonomic responses to electrical stimulation of the renal arterial nerve before and after ablation of the renal artery, Pubmed, Hyper tension, Feb. 2013 61;(2) 450-6.
Wojakowski and Tendera, Renal sympathetic nerve in pathopysiology of resistant hypertension, European Society of Cardiology, downloaded on Jun. 2013.
Chinushi et al., Hemodynamic Responses and Histological Effects of Radiofrequency catheter Ablation to renal artery Sympathetic nerve. Abstract, downloaded on Jun. 2013.
Berjano, Biomedical Engineering Online Theoretical modeling for Radiofrequency Ablation: state-of-the-art and challenges for the future, published Apr. 2006.
Young and Henneman, Reversible block of nerve Conduction by Ultrasound, Archive of Neurology vol. 4, 1961.
Ballantine et al., Focal Destruction of nervous tissue by focused ultrasound : Biophysical factors influencing its Application, Medical Acoustics Research Group, 1956.
Colucci et al., Focused Ultrasound effects on nerve action potential in vitro, Department of Radiology, Harvard Medical Scholl, Ultrasound Med Biolog. 2009, 35(10); 1773-174.
Damianou, MRI Monitoring of the effects of tissue interfaces in the penetration of high intensity focused ultrasound in kidney in vivo, Ultrasound in Med & Bilo., vol. 30 No. 9, 2004.
Daum et al., In vivo Demonstration of noninvasive thermal surgery of the liver and kidney using an ultrasonic phase array, Ultrasound in Med & Bilo., vol. 25 No. 7, 1087-1098, 1999.
Foley et al., Image guided HIFU Neurolysis of peripheral nerve to treat Spasticity and Pain, Ultrasound in Med & Bilo., vol. 30 No. 9, 1199-1207, 2004.
Foley et al., Image guided High-Intensity focused Ultrasound for Condition block of peripheral nerves, Biomed Engineering, vol. 35 No. 1, 2007.
Zhang and Solomon, Nerve Ablation by high Intensity focused Ultrasound (HIFU) in swine model: Investigating HIFU as a non invasive Nerve block tool, WCIO 2011. Abstract.
Hynynen et al., Noninvasive arterial occlusion using MRI-Guided focused Ultrasound, Ultrasound in Med & Bilo., vol. 22 No. 8, 1071-1077, 1996.
Iwamoto et al., focused Ultrasound for Tactile Felling display, ICAT 2001.
Lele, Effects of Ultrasonic radiation on peripheral Nerve, with Observation on local Hearting, Experimental Neurology 8, 47-83, 1963.
Miharn et al., Temporally-Specific modification of Myelinated Axon excitability in vitro following a single ultrasound pulse,Ultrasound in Med & Bilo., 1990.
Rubin et al., Acute effects of Ultrasound on skeletal muscle oxygen tension , blood flow and capillary density, Ultrasound in Med & Bilo., vol. 16 No. 3, 271*277, 1990.
Renal sympathetic nerve ablation for Uncontrolled Hypertension, The New England journal of medicine, 932-934, 2009.
Wu et al., Preliminary Experience using high Intensity focused Ultrasound for the treatment of patient with advanced stage renal malignancy. The Journal of Urology, vol. 170, 2237-2240, 2003.
Young and Henneman, Functional Effects of focused Ultrasound on Mammalian nerves, Science New Series, vol. 134, No. 3489, 1961, 1521-1522.
Mizelle et al., Role of Renal nerve in Compensatory adaptation to chronic reduction in sodium intake, American Physiological Society, 1987.
Gibson, The Present Status of Renal Sympathectomy, California and Western Medicine, vol. 45, No. 1, 1936.
Kassab et al., Renal Denervation Attenuates the Sodium Retention and Hypertension Associated With Obesity, Hypertension, 1997. Abstract.
Winternitz et al., Role of the Renal Sympathetic Nerves in the Development and Maintenance of Hypertension in the Spontaneously Hypertensive Rat, J. Clin Invest 66(5), 1980. Abstract.
Augustyniak et al., Sympathetic overactivity as a cause of hypertension in chronic renal failure, Hypertension vol. 20, Issue 1, 2002. Abstract.
Brief introduction to bioimpedance (from www.ucl.ac.uk-medphys-research-eit).
Fletcher, Effect of episodic hypoxia on sympathetic activity and blood pressure, Respyration Pysiology, vol. 119, issue 2-3, 2000. Abstract.
Fletcher et al., Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system, Journal of Applied physiology, 2001.
Illis, Spinal Cord Synapses in the Cat: The Reaction of the Boutons Termineaux at the Motoneurone Surface to Experimental Denervation, Brain a Journal of Neurology, vol. 87 issue 3, 1963, First page only.
Kopelman et al., Upper dorsal thoracoscopic sympathectomy for palmar hyperhidrosis. The use of harmonic scalpel versus diathermy. Ann Chir Gynaecol. 2001;90(3):203-5. Abstract.
Hashmonai et al., Thoracoscopic sympathectomy for palmar hyperhidrosis, Surgical Endoscopy May 2001, vol. 15, Issue 5, pp. 435-441.
Yoshimoto et al., Relationship between renal sympathetic nerve activity and renal blood flow during natural behavior in rats, American Journal of Physiology vol. 286, 2004.
DiBona. Dynamic Analysis of patterns of renal sympathetic nerve activity: Implications of renal functions, Exp Physiol. 90.2 pp. 159-161, 2004.
Valente et al., Laparoscopic renal denervation for intractable ADPKD-related pain, Nephrology Dialysis Transplantation vol. 6 issue 1, 2000.
An International Search Report and a Written Opinion both dated Aug. 11, 2015 which issued during of the prosecution of Applicant's PCT/IB2015/053350.
An International Preliminary Report on Patentability dated Nov. 8, 2016, which issued during the prosecution of Applicant's PCT/IB2015/053350.
An Advisory Action dated Aug. 8, 2016, which issued during the prosecution of U.S. Appl. No. 13/771,853.
European Search Report dated Jun. 7, 2016, which issued during the prosecution of Applicant's European App No. 13850508.6.
Schwarz et al;(2015) Autonomix presentation at TCT—Guidewire-Based Autonomic Neural Sensing From the Artery Lumen.
An International Search Report and a Written Opinion both dated Apr. 17, 2014 which issued during the prosecution of Applicant's PCT/IL2013/050903.
Luscher TF, Mahfoud F. Renal nerve ablation after symplicity htn-3: Confused at the higher level? Eur Heart J. 2014;35:1706-1711.
Lu (2015) Selective Proximal Renal Denervation Guided by Autonomic Responses Evoked via High-Frequency Stimulation in a Preclinical Canine Model.
Straub et al., ‘A bacteria-induced switch of sympathetic effector mechanisms augments local inhibition of TNF-a and IL-6 secretion in the spleen’ Jul. 2000 The FASEB Journal vol. 14 No. 10 1380-1388.
Gestel et al., ‘Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD)’ J Thorac Dis 2010; 2:215-222.
Hering et al., ‘Renal Denervation in Moderate to Severe CKD’ J Am Soc Nephrol. [Jul. 2012]; 23(7): 1250-1257.
Jonson et al, ‘Afferent electrical stimulation of mesenteric nerves inhibits duodenal HCO3 secretion via a spinal reflex activation of the splanchnic nerves in the rat’ [1988] Acta Physiologica Scandinavica, 133: 545-550. doi: 10.1111/j.1748-1716.1988.tb08439.x.
Jonson et al., ‘Splanchnic nerve stimulation inhibits duodenal HC03—secretion in the rat’ Am J Physiol. [Dec. 1988];255 (6 Pt 1):G709-12.
Schwan, H.P. and Kay, C.F., 1956. Specific resistance of body tissues.Circulation Research, 4(6), pp. 664-670.
Kees et al., ‘Via beta-adrenoceptors, stimulation of extrasplenic sympathetic nerve fibers inhibits lipopolysaccharideinduced TNF secretion in perfused rat spleen’ J Neuroimmunol. Dec. 2003;145(1-2):77-85.
pcta.org, ‘New (Dec. 6, 2013) Medtronic Multi-Electrode Renal Denervation Device Gets CE Mark and Australian Approval’ http://www.ptca.org/news/2013/1206_MEDTRONIC_SYMPLICITY.html.
BusinessWire, ‘St. Jude Medical Receives European Approval for New Renal Denervation System That Reduces Total Ablation Time by More Than 80 Percent’ (Aug. 29, 2013) 2013 European Society of Cardiology.
mananatomy.com, ‘Duodenum’ http://www.mananatomy.com/digestive-system/duodenum.
Rosas-Ballina et al., ‘Splenic nerve is required for cholinergic anti-inflammatory pathway control of TNF in endotoxemia’ Aug. 5, 2008, vol. 105, No. 31 www.pnas.org/cgi/doi10.1073/pnas.0803237105.
Krum, H., et al. “Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system.” Circulation 123.2 (2011): 209.
Kilgore, Kevin L., et al. “Combined direct current and high frequency nerve block for elimination of the onset response.” Engineering in Medicine and Biology Society, 2009. EMBC 2009. Annual International Conference of the IEEE. IEEE, 2009.
Bohm (2014) Symplicity HTN-3 trial_ what is it and what does it mean?
Ruilope (2014) Was there real denervation in the Symplicity HTN-3 trial.
Esler (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial).
Renal Catheterization—SymplicityTM Renal Denervation System—downloaded from medtronicrdn.com Jun. 26, 2013.
An Office Action dated Mar. 11, 2016, which issued during the prosecution of U.S. Appl. No. 13/771,853.
Persu A, Jin Y, Fadl Elmula FE, Jacobs L, Renkin J, Kjeldsen S. Renal denervation after symplicity htn-3: An update.Curr Hypertens Rep. 2014;16:460.
Renal denervation and symplicity htn-3: “Dubium sapientiae initium” (doubt is the beginning of wisdom). Circ Res. 2014;115:211-214.
Patel HC, Hayward C, Di Mario C. Symplicity htn 3: The death knell for renal denervation in hypertension? Glob Cardiol Sci Pract. 2014;2014:94-98.
An Office Action dated Jan. 8, 2015, which issued during the prosecution of U.S. Appl. No. 13/771,853.
An International Preliminary Report on Patentability dated May 5, 2015, which issued during the prosecution of Applicant's PCT/IL2013/050903.
Changfeng (2009) Analysis of nerve conduction block induced by direct current.
Tsui (2008) Chapter 2 of Atlas of ultrasound and nerve stimulation guided regional anesthesia.
Changfeng (2005) Simulation of nerve block by high frequency sunusoidal electrical current.
Warchol-Celinska E, Januszewicz A, Prejbisz A, Kadziela J. Renal denervation after the symplicity htn-3 trial. Postepy Kardiol Interwencyjnej. 2014;10:75-77.
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research Circulation. 2008.
Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: Novel implications for an old concept. Hypertension. 2009;54:1195-1201.
Esler MD, Bohm M, Sieved H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the Symplicity htn-2 randomized clinical trial. Eur Heart J. 2014;35:1752-1759.
“Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study” , Gal et al., Journal of Human Hypertension (2014), 1-4, Macmillan Publishers Limited.
Sarafidis PA, Bakris GL. Resistant hypertension: An overview of evaluation and treatment. J Am Coll Cardiol. 2008;52:1749-1757.
Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U, Bohm M. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419-424.
Kjeldsen SE, Fadl Elmula FE, Persu A, Jin Y, Staessen JA. Renal sympathetic denervation in the aftermath of symplicity htn-Blood Press. 2014;23:256-261.
Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: Rationale and design of the symplicity htn-3 trial. Clin Cardiol. 2012;35:528-535.
U.S. Appl. No. 62/158,139, filed May 7, 2015.
Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: Final 3-year report of the symplicity htn-1 study. Lancet. 2014;383:622-629.
Esler M. Illusions of truths in the symplicity htn-3 trial: Generic design strengths but neuroscience failings. J Am Soc Hypertens. 2014;8:593-598.
Schmieder RE. Hypertension: How should data from symplicity htn-3 be interpreted? Nat Rev Cardiol. 2014;11:375-376.
Pathak A, Ewen S, Fajadet J, Honton B, Mahfoud F, Marco J, Schlaich M, Schmieder R, Tsioufis K, Ukena C, Zeller T. From symplicity htn-3 to the renal denervation global registry: Where do we stand and where should we go? Eurointervention. 2014;10:21-23.
Pokushalov, Evgeny, et al. “A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. ”Journal of the American College of Cardiology 60.13 (2012): 1163-1170.
Ruilope, L.M. and Arribas, F., 2014. Resistant Hypertension and Renal Denervation. Considerations on the Results of the Symplicity HTN-3 Trial.Revista Española de Cardiología, 67(11), pp. 881-882.
An Office Action dated Nov. 30, 2017, which issued during the prosecution of U.S. Appl. No. 14/794,737.
An Office Action dated Dec. 15, 2017, which issued during the prosecution of U.S. Appl. No. 14/795,529.
An International Search Report and a Written Opinion both dated Dec. 14, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050967.
An International Search Report and a Written Opinion both dated Nov. 10, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050533.
An International Search Report and a Written Opinion both dated May 24, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050029.
An Invitation to pay additional fees dated Mar. 28, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050029.
Notice of Allowance together with the English translation dated May 4, 2017 which issued during the prosecution of Chinese Patent Application No. 2013800692612.
An Office Action dated Jun. 15, 2017, which issued during the prosecution of U.S. Appl. No. 14/440,431.
An Invitation to pay additional fees dated Sep. 11, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050533.
An Office Action dated Apr. 6, 2017, which issued during the prosecution of U.S. Appl. No. 13/771,853.
European Search Report dated May 9, 2017, which issued during the prosecution of Applicant's European App No. 16203956.4.
An English translation of an Office Action dated Nov. 18, 2016, which issued during the prosecution of Chinese Patent Application No. 201380069261.2.
An Office Action dated Sep. 6, 2018, which issued during the prosecution of U.S. Appl. No. 15/001,615.
An Office Action dated May 15, 2018, which issued during the prosecution of U.S. Appl. No. 14/972,756.
An International Search Report and a Written Opinion both dated Jun. 11, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050231.
An Office Action dated Feb. 21, 2019, which issued during the prosecution of U.S. Appl. No. 15/330,790.
Related Publications (1)
Number Date Country
20160324572 A1 Nov 2016 US
Provisional Applications (1)
Number Date Country
62158139 May 2015 US